Skip to main content

Clinical trial ORIENT-15

A Multicenter, Double-blind, Randomised Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-line Treatment of Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Organ Esophagus
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Innovent Biologics (Suzhou) Co., Ltd.
EudraCT Identifier 2020-000533-40
Last update